Galderma’s diverse portfolio and educational efforts will be highlighted in 16 posters, and two sponsored symposia, exploring insights from the ground-breaking ‘NEXT by Galderma’ future aesthetic trends report and the use of Sculptra for the body, as we celebrate its 25th anniversary
Galderma will present pivotal clinical data on Restylane SHAYPE, the latest innovation complementing the Restylane portfolio, powered by the next generation of hyaluronic acid technology, NASHA HD, which supports its safe and effective use for augmentation and correction of chin retrusion1
Results showing high patient-reported satisfaction and improved wellbeing through six months after treatment with RelabotulinumtoxinA, an investigational highly-active, innovative, complex-free, and ready-to-use liquid neuromodulator, will also be presented2,3
ZUG, Switzerland--(BUSINESS WIRE)--Galderma will present the latest updates from its broad portfolio of clinically-proven and holistic range of aesthetic treatments at the 22nd Aesthetic & Anti-Aging Medicine World Congress (AMWC) on March 27-29, 2024. The diversity of Galderma’s portfolio, designed to meet the individual needs of healthcare professionals and patients, will be showcased in 16 research posters – including data from the world’s most diverse range of fillers (Restylane®), leading neuromodulator portfolio (RelabotulinumtoxinA, Alluzience® and Azzalure®) and original biostimulator (Sculptra®) – as well as two symposia and a booth, which will host an array of live demonstrations and ‘Meet the Expert’ sessions.
|
“Galderma’s extensive activities at AMWC demonstrate our commitment to pushing the boundaries of injectable aesthetics, to anticipate and address tomorrow’s needs today. By evolving and expanding our existing treatments, developing new innovations, and conducting cutting-edge research into the groundbreaking trends that are anticipated to drive the future of aesthetics, our future-facing approach ensures we continue to deliver the best for healthcare professionals and patients.”
BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA
|
|
